Levels of brain related proteins in cerebrospinal fluid: An aid in the differential diagnosis of parkinsonian disorders

被引：48

作者：

Constantinescu, Radu ^{[1
]}

Zetterberg, Henrik ^{[2
]}

Holmberg, Bjorn ^{[1
]}

Rosengren, Lars ^{[1
]}

机构：

[1] Sahlgrens Univ Hosp, Dept Neurol, S-41345 Gothenburg, Sweden

[2] Sahlgrens Univ Hosp, Dept Psychiat & Neurochem, S-43180 Molndal, Sweden

来源：

PARKINSONISM & RELATED DISORDERS | 2009年 / 15卷 / 03期

关键词：

Parkinsonian disorders; Differential diagnosis; Brain related proteins; Cerebrospinal fluid; MULTIPLE-SYSTEM ATROPHY; FIBRILLARY ACIDIC PROTEIN; PROGRESSIVE SUPRANUCLEAR PALSY; NEUROFILAMENT LIGHT-CHAIN; NEURON-SPECIFIC ENOLASE; MYELIN BASIC-PROTEIN; TOTAL TAU-PROTEIN; ALPHA-SYNUCLEIN; CSF-NEUROFILAMENT; NEURODEGENERATIVE DISEASES;

D O I：

10.1016/j.parkreldis.2008.05.001

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

Parkinsonian disorders Such as Parkinson's disease (PD), Multiple system atrophy (MSA), progressive supranuclear palsy (PSP), and cortico-basal degeneration (CBD), are a large group of common neurodegenerative diseases. The initial differential diagnosis can be extremely challenging with major implications for prognosis. The 42 amino acid fragment of amyloid-beta (A beta 42), neurofilament light chain (NFL), neurofilament heavy chain (pNFH), tall protein, glial fibrillary acidic protein (GFAP), neuron specific enolase (NSE), S-10013 protein, and myelin basic protein (MBP) are brain related proteins (BRP) present in neurons and glia cells. They are released in the cerebrospinal fluid (CSF) after brain tissue damage caused by a variety of neurological diseases, including the parkinsonian disorders. A review of the literature shows that, carefully interpreted, the CSF levels of BRP can be Of value in the differential diagnosis of parkinsonian disorders. (C) 2008 Elsevier Ltd. All rights reserved.

引用

页码：205 / 212

页数：8

共 62 条

[1] Abdi F, 2006, J ALZHEIMERS DIS, V9, P293
[2] CSF biomarker profiles do not differentiate between the cerebellar and parkinsonian phenotypes of multiple system atrophy
Abdo, W. F.
de Warrenburg, B. P. C. van
Kremer, H. P. H.
Bloem, B. R.
Verbeek, M. M.
[J]. PARKINSONISM & RELATED DISORDERS, 2007, 13 (08) : 480 - 482
[3] CSF neurofilament light chain and tau differentiate multiple system atrophy from Parkinson's disease
Abdo, W. Farid
Bloem, Bastiaan R.
Van Geel, Wieneke J.
Esselink, Rianne A. J.
Verbeek, Marcel M.
[J]. NEUROBIOLOGY OF AGING, 2007, 28 (05) : 742 - 747
[4] Cerebrospinal fluid analysis differentiates multiple system atrophy from Parkinson's disease
Abdo, WF
de Jong, D
Hendriks, JCM
Horstink, MWIM
Kremer, BPH
Bloem, BR
Verbeek, MM
[J]. MOVEMENT DISORDERS, 2004, 19 (05) : 571 - 579
[5] β-amyloid (Aβ) protein in cerebrospinal fluid as a biomarker for Alzheimer's disease
Andreasen, N
Blennow, K
[J]. PEPTIDES, 2002, 23 (07) : 1205 - 1214
[6] Cerebrospinal fluid tau levels in neurodegenerative diseases with distinct tau-related pathology
Arai, H
Morikawa, Y
Higuchi, M
Matsui, T
Clark, CM
Miura, M
Machida, N
Lee, VMY
Trojanowski, JQ
Sasaki, H
[J]. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1997, 236 (02) : 262 - 264
[7] DETERMINATION OF S-100 AND GLIAL FIBRILLARY ACIDIC PROTEIN CONCENTRATIONS IN CEREBROSPINAL-FLUID AFTER BRAIN INFARCTION
AURELL, A
ROSENGREN, LE
KARLSSON, B
OLSSON, JE
ZBORNIKOVA, V
HAGLID, KG
[J]. STROKE, 1991, 22 (10) : 1254 - 1258
[8] Ubiquitin-proteasome system and Parkinson's diseases
Betarbet, R
Sherer, TB
Greenamyre, JT
[J]. EXPERIMENTAL NEUROLOGY, 2005, 191 : S17 - S27
[9] tau protein in cerebrospinal fluid - A biochemical marker for axonal degeneration in Alzheimer disease?
Blennow, K
Wallin, A
Agren, H
Spenger, C
Siegfried, J
Vanmechelen, E
[J]. MOLECULAR AND CHEMICAL NEUROPATHOLOGY, 1995, 26 (03) : 231 - 245
[10] Full length α-synuclein is present in cerebrospinal fluid from Parkinson's disease and normal subjects
Borghi, R
Marchese, R
Negro, A
Marinelli, L
Forloni, G
Zaccheo, D
Abbruzzese, G
Tabaton, M
[J]. NEUROSCIENCE LETTERS, 2000, 287 (01) : 65 - 67

← 1 2 3 4 5 6 7 →